Acute leukemia Cancer Leukaemia of unspecified cell type
Conditions
Interventions
Tumor DNA and RNA are extracted from bone marrow and/or peripheral blood samples collected as part of standard diagnostics. An additional sample (skin biopsy, buccal swab or other tissue) may be colle
Sponsors
Karolinska University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with diagnosed or suspected acute leukemia, for whom a referral is written for genetic diagnostics 2. Patients of any age can be included
Exclusion criteria
Exclusion criteria: Patients or guardians that are unable to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage of acute leukemia patients for whom all mandatory genetic aberrations found by SoC are also detected by WGTS is measured by comparison of variants retrieved from WGTS and SoC, respectively, after completion of patient inclusion 2. Percentage of acute leukemia patients for whom genetic variants relevant for classification or risk stratification are identified by WGTS but not by SoC is measured by comparison of variants retrieved from WGTS and SoC, respectively, after completion of patient inclusion | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percentage of patients for whom WGTS analysis and interpretation is successful in a given timeframe is measured by comparison of the number of days needed for WGTS analysis of each patient to the required turnaround-time, after completion of patient inclusion 2. Percentage of acute leukemia patients for whom patient management and/or therapy decision is changed based on variants only detected by WGTS is measured by analysis of patient journals/health records, after completion of patient inclusion 3. Micro-costing of WGTS compared to SoC is measured by comparison of costs associated with WGTS and SoC, respectively, after initiation of the study | — |
Countries
Sweden
Contacts
Public ContactRichard Rosenquist Brandell
Outcome results
None listed